Alvotech, a leading and promising biotechnology company excelling in the manufacture and establishment of biosimilar drugs for patients globally, showed excitement about its new launches. The launches are yet to land in the first-in-market biosimilar for Gobivaz® (golimumab) in Europe. The Alvotech biosimilar to Simponi® (golimumab) is also called as AVT05 (autoinjector and prefilled syringe). Gobivaz is one of the first commercialized biosimilar to Simponi globally. It is marketed across Europe exclusively by the company’s partner Advanz Holdco Limited.
The introduction of Gobivaz is backed by a National Health Service (NHS) England tender award in the United Kingdom. This acquisition decision delivers a well-precised framework for equipping the same within NHS services and mirrors the system’s target on enhancing the reach to the quality level of biologic treatment alternatives for immune-mediated inflammatory diseases. With Advanz Pharma already having its strong footprint in Europe for simponi the, Alvotech will take this partnership as an opportunity to position its new launches in the European healthcare sector.
The availability of the new products will be throughout EEA markets, which will align with reimbursement processes and national pricing. Chairman and Chief Executive Officer of Alvotech, Robert Wessman, said, “We fully welcome the introduction of Gobivaz into the clinical practice throughout Europe for its official entry to the market as the first ever biosimilar to Simponi globally. Our biosimilar marks a fundamental treatment alternative for individuals, and the NHS England tender contributes to our focus on extending access to high-quality biologic drugs.”
This approval of Gobivaz was backed by the robust preclinical, clinical and analytical studies that illustrate biosimilarity to the similar or suitable product. Gobivaz is screened and accessible in the same dosage and presentation forms as Simponi. It’s also manufactured at Alvotech’s Iceland-based facility. This core connection with the Advanz Simponi is building trust and opportunity for Alvotech to continue this partnership and redefine the new launch following its existing Simponi.
For Alvotech, the partnership with Advanz Pharma has been fruitful, and further, it will grow stronger and smarter with this on the way to new launches. This confidence resonates with the long-standing and perfect decisions of both entities to partner and propel their position as well as business in the vast healthcare sector. Europe will soon witness Gobivaz's potential in their nearest pharmaceutical store and healthcare space.
Mansi Kadam is a market research writer with over 3 years of experience analyzing trends in the healthcare industry. At Towards Healthcare, she covers innovations in medical sector, sustainability initiatives, and the evolving regulatory landscape.
